NEW YORK, July 11, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC; OTCQX: QNNTF), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, has qualified to trade on the OTCQX® Best Market.
Quantum Genomics begins trading today on OTCQX under the symbol "QNNTF." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"Trading on OTCQX will enable Quantum Genomics to provide U.S. investors with access to invest through a U.S. based, dollar denominated security. Allowing Quantum Genomics to expand its shareholder base and visibility in the U.S. market without incurring the high cost and duplicative regulatory requirements of a U.S. stock exchange listing. We look forward to being part of Quantum Genomics' continued growth and success," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group.
"Quantum Genomics is very pleased to join the group of high quality international firms in the healthcare sector already trading on OTCQX. We believe trading on OTCQX will facilitate the access to our stock in the US market which is strategic for us, both operationally and financially," added Marc Karako, Director and CFO of Quantum Genomics.
Quantum Genomics was sponsored for OTCQX by Berns & Berns, a qualified 3rd party firm responsible for providing guidance on OTCQX requirements and recommending membership.
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure. The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes. Quantum Genomics is listed on the Euronext Growth market in Paris (ISIN code FR0011648971, Ticker ALQGC) and trades on the OTCQX Best Market (OTCQX: QNNTF). The Company has offices in Paris, France, and New York, NY, USA.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, [email protected]
SOURCE OTC Markets Group Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article